loading page

Additional biomarker other than HBsAg is required to determine Hepatitis B virus (HBV) functional cure in HIV/HBV coinfection
  • +5
  • Linghua Li,
  • Fei Gu,
  • Kun Zeng,
  • Xianglong Lan,
  • Yaozu He,
  • Feng Li,
  • Xiaoping Tang,
  • Fengyu Hu
Linghua Li
Guangzhou Eighth People's Hospital

Corresponding Author:llheliza@126.com

Author Profile
Fei Gu
Guangzhou Eighth People's Hospital
Author Profile
Kun Zeng
Guangzhou Eighth People's Hospital
Author Profile
Xianglong Lan
Guangzhou Eighth People's Hospital
Author Profile
Yaozu He
Guangzhou Eighth People's Hospital
Author Profile
Feng Li
Guangzhou Eighth People's Hospital
Author Profile
Xiaoping Tang
Guangzhou Eighth People's Hospital
Author Profile
Fengyu Hu
Guangzhou Eighth People's Hospital
Author Profile

Abstract

Among 1550 human immunodeficiency virus (HIV)/Hepatitis B virus (HBV) coinfected individuals receiving antiretroviral therapy (ART) over three years in Guangzhou, China, individuals (8.2%) achieved HBsAg loss. HBsAg loss was positively associated with a longer treatment (median 6.57 years) and a lower HBsAg level (median 645.2 COI) at the baseline. However, HBV pre-genomic RNA (pgRNA), a promising viral biomarker for asserting HBV functional cure, was still detected in 43.9% (44/98) of them, implying an active HBV replication in the HBsAg loss individuals. Our observation suggested that HBsAg loss alone could not reliably predict HBV functional cure in HIV/HBV coinfection.
Submitted to Journal of Medical Virology
04 Mar 2024Review(s) Completed, Editorial Evaluation Pending
07 May 20241st Revision Received
02 Jun 2024Review(s) Completed, Editorial Evaluation Pending
11 Jun 2024Editorial Decision: Accept